Skip to content
2000
Volume 8, Issue 3
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

The ubiquitin proteasome pathway is the most significant intracellular proteolytic pathway. The target proteins are usually ubiquitinated prior to degradation by the proteasome; however, ubiquitin-independent targeting mechanisms have also been reported (e.g., the antizyme-mediated degradation of ornithine decarboxylase). Aberrations in the components of the ubiquitin proteasome pathway are commonly observed in many cancers, and uncontrolled growth of cancer cells can result either from stabilization of oncoproteins (e.g., c-jun) or increased degradation of tumor suppressor proteins (e.g., p53). In addition, due to the pleiotropic functions of the ubiquitin proteasome pathway in cells, there is great interest in developing inhibitors to specifically block this pathway for cancer treatment. This review summarizes the recent literature and several patented inventions on the ubiquitin proteasome pathway with respect to its role in cancer development and treatment.

Loading

Article metrics loading...

/content/journals/pra/10.2174/1574891X113089990033
2013-09-01
2025-09-29
Loading full text...

Full text loading...

/content/journals/pra/10.2174/1574891X113089990033
Loading

  • Article Type:
    Research Article
Keyword(s): Apoptosis; bortezomib; cancer; inhibitor; proteasome; proteolysis; ubiquitin
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test